Not yet recruiting
Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
NCT07129161
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, China
- The Second Affiliated Hospital of Air Force Medical University Xi'an, China